|
1
|
Gottardo NG, Hansford JR, McGlade JP,
Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay
M, et al: Medulloblastoma Down Under 2013: A report from the third
annual meeting of the International Medulloblastoma Working Group.
Acta Neuropathol. 127:189–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kool M, Korshunov A, Remke M, Jones DT,
Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van
Meeteren A, van Vuurden D, et al: Molecular subgroups of
medulloblastoma: An international meta-analysis of transcriptome,
genetic aberrations, and clinical data of WNT, SHH, Group 3, and
Group 4 medulloblastomas. Acta Neuropathol. 123:473–484. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Packer RJ, Cogen P, Vezina G and Rorke LB:
Medulloblastoma: Clinical and biologic aspects. Neuro-oncol.
1:232–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Packer RJ, Sutton LN, Goldwein JW,
Perilongo G, Bunin G, Ryan J, Cohen BH, D'Angio G, Kramer ED,
Zimmerman RA, et al: Improved survival with the use of adjuvant
chemotherapy in the treatment of medulloblastoma. J Neurosurg.
74:433–440. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
del Charco JO, Bolek TW, McCollough WM,
Maria BL, Kedar A, Braylan RC, Mickle JP, Buatti JM, Mendenhall NP
and Marcus RB Jr: Medulloblastoma: Time-dose relationship based on
a 30-year review. Int J Radiat Oncol Biol Phys. 42:147–154. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Northcott PA, Korshunov A, Witt H,
Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins
CE, French P, et al: Medulloblastoma comprises four distinct
molecular variants. J Clin Oncol. 29:1408–1414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bronner C, Achour M, Arima Y, Chataigneau
T, Saya H and Schini-Kerth VB: The UHRF family: Oncogenes that are
drugable targets for cancer therapy in the near future? Pharmacol
Ther. 115:419–434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muto M, Kanari Y, Kubo E, Takabe T,
Kurihara T, Fujimori A and Tatsumi K: Targeted disruption of Np95
gene renders murine embryonic stem cells hypersensitive to DNA
damaging agents and DNA replication blocks. J Biol Chem.
277:34549–34555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mudbhary R, Hoshida Y, Chernyavskaya Y,
Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson
RT, et al: UHRF1 overexpression drives DNA hypomethylation and
hepatocellular carcinoma. Cancer Cell. 25:196–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pi JT, Lin Y, Quan Q, Chen LL, Jiang LZ,
Chi W and Chen HY: Overexpression of UHRF1 is significantly
associated with poor prognosis in laryngeal squamous cell
carcinoma. Med Oncol. 30:6132013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Daskalos A, Oleksiewicz U, Filia A,
Nikolaidis G, Xinarianos G, Gosney JR, Malliri A, Field JK and
Liloglou T: UHRF1-mediated tumor suppressor gene inactivation in
nonsmall cell lung cancer. Cancer. 117:1027–1037. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geng Y, Gao Y, Ju H and Yan F: Diagnostic
and prognostic value of plasma and tissue ubiquitin-like,
containing PHD and RING finger domains 1 in breast cancer patients.
Cancer Sci. 104:194–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou L, Zhao X, Han Y, Lu Y, Shang Y, Liu
C, Li T, Jin Z, Fan D and Wu K: Regulation of UHRF1 by miR-146a/b
modulates gastric cancer invasion and metastasis. FASEB J.
27:4929–4939. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang D, Xue H, Yu Y, Lv F, You W and
Zhang B: Elevated expression of UHRF1 predicts unfavorable
prognosis for patients with hepatocellular carcinoma. Int J Clin
Exp Pathol. 8:9416–9421. 2015.PubMed/NCBI
|
|
15
|
Wang F, Yang YZ, Shi CZ, Zhang P, Moyer
MP, Zhang HZ, Zou Y and Qin HL: UHRF1 promotes cell growth and
metastasis through repression of p16ink4a in colorectal
cancer. Ann Surg Oncol. 19:2753–2762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang GL, Zhang LH, Bo JJ, Chen HG, Cao M,
Liu DM and Huang YR: UHRF1 is associated with tumor recurrence in
non-muscle-invasive bladder cancer. Med Oncol. 29:842–847. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jazirehi AR, Arle D and Wenn PB: UHRF1: A
master regulator in prostate cancer. Epigenomics. 4:251–252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang ZY, Cai JJ, Hong J, Li KK, Ping Z,
Wang Y, Ng HK, Yao Y and Mao Y: Clinicopathological analysis of
UHRF1 expression in medulloblastoma tissues and its regulation on
tumor cell proliferation. Med Oncol. 33:992016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
21
|
Sato F, Tsuchiya S, Meltzer SJ and Shimizu
K: MicroRNAs and epigenetics. FEBS J. 278:1598–1609. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang
L, Li G, Chen HH and Li XP: MicroRNA-378 functions as an onco-miR
in nasopharyngeal carcinoma by repressing TOB2 expression. Int J
Oncol. 44:1215–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang GJ, Zhou H, Xiao HX, Li Y and Zhou
T: MiR-378 is an independent prognostic factor and inhibits cell
growth and invasion in colorectal cancer. BMC Cancer. 14:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen QG, Zhou W, Han T, Du SQ, Li ZH,
Zhang Z, Shan GY and Kong CZ: MiR-378 suppresses prostate cancer
cell growth through downregulation of MAPK1 in vitro and in vivo.
Tumour Biol. 37:2095–2103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li B, Wang Y, Li S, He H, Sun F, Wang C,
Lu Y, Wang X and Tao B: Decreased expression of miR-378 correlates
with tumor invasiveness and poor prognosis of patients with glioma.
Int J Clin Exp Pathol. 8:7016–7021. 2015.PubMed/NCBI
|
|
26
|
Venkataraman S, Birks DK, Balakrishnan I,
Alimova I, Harris PS, Patel PR, Handler MH, Dubuc A, Taylor MD,
Foreman NK, et al: MicroRNA 218 acts as a tumor suppressor by
targeting multiple cancer phenotype-associated genes in
medulloblastoma. J Biol Chem. 288:1918–1928. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li KK, Pang JC, Lau KM, Zhou L, Mao Y,
Wang Y, Poon WS and Ng HK: MiR-383 is downregulated in
medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol.
23:413–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi JA, Lu DL, Huang X and Tan W: miR-219
inhibits the proliferation, migration and invasion of
medulloblastoma cells by targeting CD164. Int J Mol Med.
34:237–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Silber J, Hashizume R, Felix T, Hariono S,
Yu M, Berger MS, Huse JT, VandenBerg SR, James CD, Hodgson JG, et
al: Expression of miR-124 inhibits growth of medulloblastoma cells.
Neuro Oncol. 15:83–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang GJ, Zhou H, Xiao HX, Li Y and Zhou
T: MiR-378 is an independent prognostic factor and inhibits cell
growth and invasion in colorectal cancer. BMC Cancer. 14:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fei B and Wu H: MiR-378 inhibits
progression of human gastric cancer MGC-803 cells by targeting
MAPK1 in vitro. Oncol Res. 20:557–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
